BRCA1 and breast cancer: Nonetheless, the efficacy of PARPi has been demonstrated amongst breast cancer patients with somatic mutations in BRCA1/2, including a cohort of 16 metastatic patients, where an ORR of 50% was observed (90% CI, 28% to 72%) [51,93].